Byondis intends to bag commercialisation partner for breast cancer ADC by 2H21
Byondis is working with the CRO Syneos Health to manage the Phase III SYD985 trial dubbed TULIP. Credit: Angiola Harry on Unsplash
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
